logo
HMPV: Virus cases on the rise in UK as doctors issue ‘mask up' warning

HMPV: Virus cases on the rise in UK as doctors issue ‘mask up' warning

Yahoo28-01-2025

The rate of positive tests for a virus that swept hospitals in China is on the rise in the England, according to official figures.
Latest UK Health Security Agency data show one in 20 (5 per cent) of hospital swabs for respiratory infections in England came back positive for human metaphneumovirus (HMPV) in the week ending January 19.
It's the highest recorded rate of the virus so far this winter season, and above the 4.18 per cent of cases recorded at the start of 2024 - but still well below the 10 per cent recorded in 2021.
UKHSA, which does not publish case numbers, said the level of HMPV in England is currently 'medium' based on the almost 8,000 samples tested. Doctors have urged people with symptoms of a respiratory illness to wear a face mask when out in public.
The age group with the highest proportion of HMPV cases was those aged 80 and over, soaring to 7.3 per cent and well above pre-Christmas levels. Cases have also risen to about 7 per cent in children up to the age of five.
From GP swaps, 1.9 per cent came back positive for HMPV.
Earlier this year photos and videos of people wearing masks in hospitals in China emerged as the virus swept through northern Chinese provinces over winter, particularly affecting younger children.
Reports of overcrowding in Chinese hospitals related to the outbreak sparked some alarm, and the European Union began monitoring cases.
The European Centre for Disease Prevention and Control said while cases across Europe were not unusual for this time of year, it would continue to assess the situation.
HMPV is a common virus that cause cold-like symptoms, but can be serious for vulnerable people including the elderly and young children. Experts say that the virus is neither new, nor poses a threat to global health.
The virus spreads through direct contact with infected individuals or by touching contaminated surfaces, experts say. The virus was discovered in 2001 by Dutch scientists, and has since been found worldwide.
Earlier this month Dr Conal Watson, a consultant epidemiologist at the UKHSA, said cases of HMPV typically peak in January.
'Most people have had hMPV by the time they are five years old and catch it again throughout their lives,' he said.
In cases of mild illness, cases normally clear up on their own. Symptoms can include:
A cough, runny nose, nasal congestion
Sore throat
Wheezing
Shortness of breath
Athsma flare ups
In more serious cases, HMPV symptoms can include:
Acute bronchitis
Pneumonia
Dr Watson said people should help reduce the spread by washing their hands regularly and catching coughs and sneezes in tissues and throwing those used tissues away.
Dr Watson added: 'If you have symptoms such as a high temperature, cough and feeling tired and achy, try to limit your contact with others, especially those who are vulnerable.
'There are many viruses in circulation at the moment, including flu – if you have symptoms of a respiratory illness and you need to go out, our advice continues to be that you should consider wearing a face mask.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS CLARUS 700 Receives NMPA Approval in China

Yahoo

time9 hours ago

  • Yahoo

ZEISS CLARUS 700 Receives NMPA Approval in China

ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation. "ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow." "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China. Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. More information about the CLARUS® 700 from ZEISS can be found here. 1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS CLARUS 700 Receives NMPA Approval in China

Yahoo

time10 hours ago

  • Yahoo

ZEISS CLARUS 700 Receives NMPA Approval in China

ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation. "ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow." "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China. Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. More information about the CLARUS® 700 from ZEISS can be found here. 1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia:

Chinese scientist faces hearing after pathogen seized by FBI
Chinese scientist faces hearing after pathogen seized by FBI

Yahoo

time10 hours ago

  • Yahoo

Chinese scientist faces hearing after pathogen seized by FBI

(NewsNation) — A detention hearing was postponed on Thursday for Yunqing Jian, a Chinese scientist who was caught smuggling a pathogen into the U.S. last year. Jian and her boyfriend, Zunyong Liu, were charged by the FBI earlier this week with conspiracy, smuggling, making false statements and visa fraud. The FBI says Liu tried to sneak Fusarium graminearum into the country but was turned away and sent back to China after changing his story during an interrogation about red plant material discovered in his backpack. Unlicensed EMT indicted after allegedly caring for over 100 patients Jian and Liu had exchanged messages suggesting that Jian was already tending to the toxic fungus at a University of Michigan lab before Liu, a lab researcher at the university, was caught at the Detroit airport. The university does not have federal permits to handle it. The FBI acknowledged that a scientific journal described Fusarium graminearum as a potential 'agroterrorism weapon.' The pathogen is known to cause diseases in wheat, barley, maize and rice. The new court date has been announced for June 13. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store